tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Plus Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
PremiumThe FlyPlus Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
18d ago
Plus Therapeutics Signs Lease Agreement in Houston
Premium
Company Announcements
Plus Therapeutics Signs Lease Agreement in Houston
1M ago
Plus Therapeutics provides update on CNSide Diagnostic platform launch
Premium
The Fly
Plus Therapeutics provides update on CNSide Diagnostic platform launch
1M ago
Plus Therapeutics announces $1.9M advance payment from CPRIT
PremiumThe FlyPlus Therapeutics announces $1.9M advance payment from CPRIT
2M ago
Plus Therapeutics announces accreditation, certification for CNSide Diagnostics
Premium
The Fly
Plus Therapeutics announces accreditation, certification for CNSide Diagnostics
2M ago
Plus Therapeutics upgraded to Buy from Hold at D. Boral Capital
Premium
The Fly
Plus Therapeutics upgraded to Buy from Hold at D. Boral Capital
3M ago
Optimistic Buy Rating for Plus Therapeutics Driven by Strategic Financial Positioning and Clinical Advancements
PremiumRatingsOptimistic Buy Rating for Plus Therapeutics Driven by Strategic Financial Positioning and Clinical Advancements
3M ago
Plus Therapeutics reports stockholders’ equity in excess of $2.5M
Premium
The Fly
Plus Therapeutics reports stockholders’ equity in excess of $2.5M
3M ago
Buy Rating for Plus Therapeutics: Strategic Market Launch and Promising Financial Outlook
Premium
Ratings
Buy Rating for Plus Therapeutics: Strategic Market Launch and Promising Financial Outlook
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100